SCHEMBL17050428

SCHEMBL17050428

Cc1nsc2cc(C(C)C)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
SCN4A P35499 1/20 0.41
KIF11 P52732 1/20 0.40
LMNA P02545 2/20 0.38
TRPA1 O75762 1/20 0.37
PTGS1 P23219 1/20 0.37
CACNA1C Q13936 1/20 0.37
PARP15 Q460N3 1/20 0.36
PARP10 Q53GL7 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
ABL1 P00519 1/20 0.36
LCK P06239 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2609432 0.85 LMNA (0.38) NPC1RAB9ASMN1; SMN2SCN4AKIF11
SCHEMBL20048894 0.81 NPC1 (0.41) NPC1RAB9ASMN1; SMN2SCN4AKIF11
SCHEMBL23478522 0.80 KDM4E (0.48) NPC1RAB9ASMN1; SMN2SCN4AKIF11
SCHEMBL23478969 0.80 RAB9A (0.44) NPC1RAB9ASMN1; SMN2SCN4AKIF11
SCHEMBL14827036 0.77 GRM4 (0.41) NPC1RAB9ASMN1; SMN2SCN4AKIF11
SCHEMBL5985788 0.76 MAPT (0.37) NPC1RAB9AKIF11LMNAPARP15
SCHEMBL22672607 0.75 EIF4A3 (0.44) NPC1RAB9ASMN1; SMN2SCN4ALMNA
SCHEMBL1121782 0.73 CCNB2 (0.44) SMN1; SMN2KIF11LMNAPTGS1CDK5
SCHEMBL10222167 0.73 CYP2A6 (0.40) SMN1; SMN2LMNAGAAALDH1A1MEN1
SCHEMBL13202665 0.73 LSS (0.36) NPC1LMNAJAK2MAPK8CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018067704-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-04-12 WO disclosed
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE ACSS2, ACACB, ACAT2 NPC1 1419/4885RAB9A 3407/4885SMN1; SMN2 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.